Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Accumulated Expenses (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Accumulated Expenses for 6 consecutive years, with $23.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 7.61% to $23.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.2 million, a 7.61% increase, with the full-year FY2025 number at $23.2 million, up 7.61% from a year prior.
  • Accumulated Expenses was $23.2 million for Q4 2025 at PROCEPT BioRobotics, up from $21.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $23.2 million in Q4 2025 to a low of $4.6 million in Q1 2022.
  • A 5-year average of $13.2 million and a median of $13.4 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 110.95% in 2022, then grew 7.61% in 2025.
  • PROCEPT BioRobotics' Accumulated Expenses stood at $6.5 million in 2021, then soared by 107.68% to $13.4 million in 2022, then increased by 25.57% to $16.9 million in 2023, then increased by 27.55% to $21.5 million in 2024, then increased by 7.61% to $23.2 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Accumulated Expenses are $23.2 million (Q4 2025), $21.8 million (Q3 2025), and $16.3 million (Q2 2025).